TACSTD2 and cervical cancer: Next, we investigated to our knowledge for the first time, the in vitro and in vivo activity of sacituzumab govitecan, a novel ADC that couples a humanized monoclonal Trop-2 antibody and SN-38 (active metabolite of irinotecan) with a cleavable linker that is subject to time-dependent hydrolysis7, against primary cervical cancer cell lines and xenograft models.